Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02740192 · ClinicalTrials.gov registry record · Early Phase 1
Pain Control After Total Knee Arthroplasty: Benefit In Adding Single Shot Adductor Canal Block to Existing Pain Regimen Protocol?
A Early Phase 1 study, sponsored by Henry Ford Health System.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 128
- Enrollment target
NCT02740192 is a Early Phase 1 study that has completed, run by Henry Ford Health System. The registered enrollment target is 128 participants.
The verdict
NCT02740192, a Early Phase 1 study, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 128 participants
- Enrollment target
Study Summary
This is a randomized, double blinded, standard of care controlled clinical trial. All adult patients over eighteen desiring total knee arthroplasty will be eligible. The study compares pain control, opioid consumption, and physical exam findings in patients undergoing total knee arthroplasty between patients receiving adductor canal block and those who receiving periarticular injection alone.
Interventions
- DRUG Bupivacaine
- DRUG Ropivacaine
- PROCEDURE Adductor Canal Block
- PROCEDURE Periarticular Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2016-04 |
| Est. Completion | 2016-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02740192
The ClinicalTrials.gov registry entry for NCT02740192 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bupivacaine is the first listed.
NCT02740192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02740192 about?
NCT02740192 is a clinical study titled "Pain Control After Total Knee Arthroplasty: Benefit In Adding Single Shot Adductor Canal Block to Existing Pain Regimen Protocol?". This is a randomized, double blinded, standard of care controlled clinical trial. All adult patients over eighteen desiring total knee arthroplasty will be eligible. The study compares pain control, opioid consumption, and physical exam findings in patients undergoing total knee arthroplasty between...
What is the current status of trial NCT02740192?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 128 participants. The study started on 2016-04. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02740192?
The interventions under investigation include: Bupivacaine (DRUG), Ropivacaine (DRUG), Adductor Canal Block (PROCEDURE), Periarticular Injection (PROCEDURE).
Who is sponsoring clinical trial NCT02740192?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.